{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:45:40Z","timestamp":1789919140074,"version":"4.0.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"MINECO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"CSIC","doi-asserted-by":"publisher","award":["IP201880E070"],"award-info":[{"award-number":["IP201880E070"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.07.031","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T03:52:05Z","timestamp":1532577125000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism"],"prefix":"10.1016","volume":"157","author":[{"given":"Paula","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Goya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Jagerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.07.031_b0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrn3811","article-title":"Early phytocannabinoid chemistry to endocannabinoids and beyond","volume":"15","author":"Mechoulam","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.031_b0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/me.2015-1062","article-title":"Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation","volume":"29","author":"Picone","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2018.07.031_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2016.00294","article-title":"Cannabinoid receptors in the central nervous system: their signaling and roles in disease","volume":"10","author":"Kendall","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.031_b0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptors","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543776.2016.1193157","article-title":"Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update","volume":"26","author":"Morales","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2018.07.031_b0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.phrs.2017.02.023","article-title":"Emerging therapeutic targets in cancer induced bone disease: a focus on the peripheral type 2 cannabinoid receptor","volume":"119","author":"Marino","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fnins.2016.00406","article-title":"Targeting cannabinoid CB2 receptors in the central nervous system. medicinal chemistry approaches with focus on neurodegenerative disorders","volume":"10","author":"Navarro","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.031_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1744-8069-5-11","article-title":"Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine","volume":"5","author":"Garz\u00f3n","year":"2009","journal-title":"Mol. Pain."},{"key":"10.1016\/j.bcp.2018.07.031_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000068915","article-title":"The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation","volume":"12","author":"Bash","year":"2003","journal-title":"Neurosignals"},{"key":"10.1016\/j.bcp.2018.07.031_b0050","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1124\/mol.56.6.1362","article-title":"Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors","volume":"56","author":"Glass","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2018.07.031_b0060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 cannabinoid receptors as a therapeutic target \u2013 What does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0026-895X(25)10492-6","article-title":"Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors","volume":"48","author":"Felder","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.phrs.2016.06.026","article-title":"G\u03b2\u03b3 subunits\u2014different spaces, different faces","volume":"111","author":"Khan","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(24)01478-9","article-title":"Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling","volume":"53","author":"Ferguson","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2018.07.031_b0080","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1074\/jbc.R115.713313","article-title":"The B-Arrestins: multifunctional regulators of G protein-coupled receptors","volume":"291","author":"Smith","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0085","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1091\/mbc.e17-03-0198","article-title":"Retromer stops beta-arrestin 1-mediated signaling from internalized cannabinoid 2 receptors","volume":"28","author":"Nogueras-Ortiz","year":"2017","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0090","doi-asserted-by":"crossref","first-page":"ra51","DOI":"10.1126\/scisignal.2001707","article-title":"Distinct phosphorylation sites on the B2-adrenergic receptor establish a barcode that encodes differential functions of B-arrestin","volume":"4","author":"Nobles","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2018.07.031_b0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tibs.2011.06.003","article-title":"Emerging paradigms of b-arrestin-dependent seven transmembrane receptor signaling","volume":"36","author":"Shukla","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2018.01.001","article-title":"New insights into modes of GPCR activation","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-018-0077-3","article-title":"Molecular mechanism of GPCR-mediated arrestin activation","volume":"557","author":"Latorraca","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0110","first-page":"383","article-title":"Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region","volume":"40","author":"Venkatakrishnan","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tibs.2014.10.001","article-title":"Emerging structural insights into biased GPCR signaling","volume":"39","author":"Shukla","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0120","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.8b00435","article-title":"biased ligands of g protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential","author":"Tan","year":"2018","journal-title":"J. Med. Chem. ASAP"},{"key":"10.1016\/j.bcp.2018.07.031_b0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cell.2016.07.004","article-title":"GPCR-G protein-\u03b2-arrestin super-complex mediates sustained G protein signaling","volume":"166","author":"Thomsen","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0130","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the l-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2018.07.031_b0135","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nature20606","article-title":"Intracellular allosteric antagonism of the CCR9 receptor","volume":"540","author":"Oswald","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2018.07.031_b0145","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nchembio.2431","article-title":"A kinetic view of GPCR allostery and biased agonism","volume":"13","author":"Lane","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0150","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bpj.2016.07.044","article-title":"Biased allostery","volume":"111","author":"Edelstein","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.bcp.2018.07.031_b0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dor\u00e9","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0165","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1073\/pnas.1621423114","article-title":"Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket","volume":"114","author":"Sun","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2017.12.004","article-title":"Allosteric coupling of drug binding and intracellular signaling in the A 2A adenosine receptor","volume":"172","author":"Eddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0175","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14337","article-title":"New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism running","author":"Vecchio","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0180","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41467-017-01855-z","article-title":"G\u03b1iis required for carvedilol-induced \u03b21adrenergic receptor \u03b2-arrestin biased signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn400023y","article-title":"Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?","volume":"4","author":"Hopkins","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.031_b0195","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1038\/ncomms5589","article-title":"Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1","volume":"5","author":"Flores-Otero","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0200","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/mol.116.104539","article-title":"The multiple waves of cannabinoid 1 receptor signaling","volume":"90","author":"Yudowski","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2016.10.005","article-title":"Cannabinoid receptor ligand bias: implications in the central nervous system","volume":"32","author":"Laprairie","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0210","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.115.103176","article-title":"Mechanisms of biased \u03b2-arrestin-mediated signaling downstream from the cannabinoid 1 receptor","volume":"89","author":"Delgado-Peraza","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0215","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/jpet.105.089474","article-title":"Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors","volume":"315","author":"Shoemaker","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.07.031_b0220","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.1038\/ncomms13958","article-title":"Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity","volume":"8","author":"Soethoudt","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0225","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","article-title":"How ligands illuminate GPCR molecular pharmacology","volume":"170","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0230","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nchembio.2490","article-title":"Discovery of new GPCR ligands to illuminate new biology","volume":"13","author":"Roth","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.sbi.2017.04.010","article-title":"Active state structures of G protein-coupled receptors highlight the similarities and differences in the G protein and arrestin coupling interfaces","volume":"45","author":"Carpenter","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0240","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.sbi.2017.05.004","article-title":"Understanding the GPCR biased signaling through G protein and arrestin complex structures","volume":"45","author":"Zhou","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0245","doi-asserted-by":"crossref","first-page":"40989","DOI":"10.1074\/jbc.M206801200","article-title":"\u03b22 adrenergic receptor activation: Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch","volume":"277","author":"Shi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0250","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0255","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.0802515105","article-title":"High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation","volume":"105","author":"Altenbach","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2018.07.031_b0260","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.1215802","article-title":"Biased signaling pathways in \u03b22-adrenergic receptor characterized by 19F-NMR","volume":"335","author":"Liu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2018.07.031_b0265","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.1201093109","article-title":"Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2018.07.031_b0270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2017.07.002","article-title":"Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors","volume":"170","author":"Zhou","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nature12120","article-title":"Structure of active \u03b2-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide","volume":"497","author":"Shukla","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0280","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/ncomms5801","article-title":"Crystal structure of a common GPCR-binding interface for G protein and arrestin","volume":"5","author":"Szczepek","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0285","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature14656","article-title":"Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser","volume":"523","author":"Kang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0290","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1074\/jbc.M117.817890","article-title":"The arrestin-1 finger loop interacts with two distinct conformations of active rhodopsin","volume":"293","author":"Elgeti","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0295","doi-asserted-by":"crossref","first-page":"R324","DOI":"10.1016\/j.cub.2018.02.027","article-title":"The interplay of G\u03b1i and \u03b2-arrestin","volume":"28","author":"Dwivedi","year":"2018","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0300","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/mol.111.074013","article-title":"Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands","volume":"81","author":"Atwood","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0305","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.116.232561","article-title":"Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway","volume":"358","author":"Dhopeshwarkar","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.07.031_b0310","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0315","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.chembiol.2011.05.012","article-title":"Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists","volume":"18","author":"Schuehly","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2018.07.031_b0320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-015-0307-7","article-title":"4\u2019-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation","volume":"12","author":"Chicca","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bcp.2018.07.031_b0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1087057108327329","article-title":"Characterizing cannabinoid CB2receptor ligands using DiscoveRx PathHunterTM \u03b2-arrestin assay","volume":"14","author":"McGuinness","year":"2009","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2018.07.031_b0330","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1152\/ajpheart.01328.2007","article-title":"CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways","volume":"294","author":"Montecucco","year":"2008","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"10.1016\/j.bcp.2018.07.031_b0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.117.109355","article-title":"The slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence","volume":"93","author":"Lin","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/can.2015.0005","article-title":"Allosteric modulators of the CB 1 cannabinoid receptor: a structural update review","volume":"1","author":"Morales","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0345","article-title":"The future of type 1 cannabinoid receptor allosteric ligands","volume":"ASAP","author":"Alaverdashvili","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2018.07.031_b0350","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0355","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1038\/s41598-017-09808-8","article-title":"Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage","volume":"7","author":"Petrucci","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.07.031_b0360","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/2472555217748403","article-title":"Discovery of Selective Cannabinoid CB2 receptor agonists by high-throughput screening","volume":"23","author":"Ogawa","year":"2018","journal-title":"SLAS Discov. Adv. Life Sci. R&D."},{"key":"10.1016\/j.bcp.2018.07.031_b0365","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/15406580360545107","article-title":"High throughput screening technologies for direct cyclic AMP measurement","volume":"1","author":"Gabriel","year":"2003","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bcp.2018.07.031_b0370","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707347","article-title":"PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats","volume":"152","author":"Horswill","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0375","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.M113.478495","article-title":"Allosteric modulation of a cannabinoid G protein-coupled receptor binding site elucidation and relationship to g protein signaling","volume":"289","author":"Shore","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0380","doi-asserted-by":"crossref","first-page":"15453","DOI":"10.1038\/srep15453","article-title":"Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments","volume":"5","author":"Stornaiuolo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.07.031_b0385","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/bab.1589","article-title":"In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor","volume":"65","author":"Sabatucci","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.bcp.2018.07.031_b0390","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/ci5002718","article-title":"Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs","volume":"54","author":"Feng","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2018.07.031_b0395","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"ASAP","author":"Laprairie","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0400","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0405","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0410","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2017.00422","article-title":"An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol","volume":"8","author":"Morales","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0415","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbrc.2017.05.165","article-title":"GPR3 and GPR6, novel molecular targets for cannabidiol","volume":"490","author":"Laun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0420","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2017.09.001","article-title":"Cannabidiol, a novel inverse agonist for GPR12","volume":"493","author":"Brown","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2018.07.031_b0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0430","doi-asserted-by":"crossref","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.031_b0435","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.phrs.2015.07.017","article-title":"Aiming for allosterism: evaluation of allosteric modulators of CB1 in a neuronal model","volume":"99","author":"Straiker","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0440","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/jpet.116.234948","article-title":"Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay","volume":"358","author":"Mart\u00ednez-Pinilla","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.07.031_b0445","series-title":"Endocannabinoids","first-page":"1","article-title":"Endocannabinoids and their pharmacological actions","author":"Pertwee","year":"2015"},{"key":"10.1016\/j.bcp.2018.07.031_b0450","doi-asserted-by":"crossref","first-page":"20588","DOI":"10.1073\/pnas.0706980105","article-title":"Hemopressin is an inverse agonist of CB1 cannabinoid receptors","volume":"104","author":"Heimann","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.07.031_b0455","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1096\/fj.09-132142","article-title":"Novel endogenous peptide agonists of cannabinoid receptors","volume":"23","author":"Gomes","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2018.07.031_b0460","doi-asserted-by":"crossref","first-page":"36944","DOI":"10.1074\/jbc.M112.382481","article-title":"Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors","volume":"287","author":"Bauer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0465","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuropharm.2015.03.021","article-title":"Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla","volume":"98","author":"Hofer","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.07.031_b0470","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1471-4159.2010.06653.x","article-title":"Hemopressins and other hemoglobin-derived peptides in mouse brain: comparison between brain, blood, and heart peptidome and regulation in Cpefat\/fat mice","volume":"113","author":"Gelman","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.07.031_b0475","article-title":"Identification of the first synthetic allosteric modulator of the CB 2 receptors and evidence of its efficacy for neuropathic pain relief","volume":"ASAP","author":"Gado","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0480","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2018.05.019","article-title":"Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system","volume":"154","author":"Chicca","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0485","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/can.2016.0037","article-title":"Cannabinoid CB1 and CB2 receptor signaling and bias","volume":"2","author":"Ibsen","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.bcp.2018.07.031_b0490","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fendo.2014.00068","article-title":"Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics","volume":"5","author":"Khoury","year":"2014","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2018.07.031_b0495","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.ddtec.2012.07.010","article-title":"Chemogenomics of allosteric binding sites in GPCRs","volume":"10","author":"Gloriam","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bcp.2018.07.031_b0500","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1074\/jbc.R115.662759","article-title":"Novel allosteric modulators of G protein-coupled receptors","volume":"290","author":"Gentry","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.031_b0505","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuron.2017.03.016","article-title":"Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders","volume":"94","author":"Foster","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2018.07.031_b0510","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature14663","article-title":"Universal allosteric mechanism for G\u03b1 activation by GPCRs","volume":"524","author":"Flock","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.031_b0515","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.tips.2017.05.010","article-title":"Applying structure-based drug design approaches to allosteric modulators of GPCRs","volume":"38","author":"Congreve","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2018.07.031_b0520","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cell.2016.08.015","article-title":"Allosteric modulation as a unifying mechanism for receptor function and regulation","volume":"166","author":"Changeux","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.07.031_b0525","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2017.07.002","article-title":"Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics?","volume":"22","author":"Madariaga-Maz\u00f3n","year":"2017","journal-title":"Drug Discov. Today."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T01:31:01Z","timestamp":1751765461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":105,"alternative-id":["S0006295218302995"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.031","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}